Discover open access scientific publications

Search, annotate, share and cite publications

Publications by K. Reich

Transition to Ustekinumab in Patients With Moderate-To-Severe Psoriasis and Inadequate Response to Methotrexate: A Randomized Clinical Trial (TRANSIT)

British Journal of Dermatology

Dermatology

Medicine

2014

English

Secukinumab Is Superior to Fumaric Acid Esters in Treating Subjects With Moderate to Severe Plaque Psoriasis Who Are Naïve to Systemic Treatments: Results From the Randomized Controlled PRIME Trial

British Journal of Dermatology

Dermatology

Medicine

2017

English

Efficacy and Safety of Mirikizumab (LY3074828) in the Treatment of Moderate-To-Severe Plaque Psoriasis: Results From a Randomised Phase 2 Study

British Journal of Dermatology

Dermatology

Medicine

2019

English

Ixekizumab Treatment for Psoriasis: Integrated Efficacy Analysis of Three Double-Blinded, Controlled Studies (UNCOVER-1, UNCOVER-2, UNCOVER-3)

British Journal of Dermatology

Dermatology

Medicine

2018

English

060 Integrated Safety of Ixekizumab in Patients With Moderate-To-Severe Psoriasis: Results From a Pooled Analysis of 7 Clinical Trials

Journal of Investigative Dermatology

English

伊赛珠单抗对银屑病的治疗:三项双盲对照研究的综合药效分析(发现-1、发现-2、发现-3)

British Journal of Dermatology

Dermatology

Medicine

2018

English

534 Effects on CD3, Treg and TH17 Cell Numbers in Skin Biopsies After 16-Week Mirikizumab Treatment, Evaluated by an Epigenetic Assay

Journal of Investigative Dermatology

English

A 24‐week Multicentre, Randomised, Open‐label, Parallel‐group Study Comparing the Efficacy and Safety of Ixekizumab to Fumaric Acid Esters and Methotrexate in Patients With Moderate‐to‐severe Plaque Psoriasis Naïve to Systemic Treatment

British Journal of Dermatology

Dermatology

Medicine

2020

English

Safety of Guselkumab in Patients With Psoriasis Treated Through 100 Weeks

British Journal of Dermatology

Dermatology

Medicine

2019

English

059 Ixekizumab Shows No Association With MACE in Patients With Moderate-To-Severe Psoriasis: An Integrated Safety Analysis of Clinical Trials

Journal of Investigative Dermatology

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by K. Reich

Transition to Ustekinumab in Patients With Moderate-To-Severe Psoriasis and Inadequate Response to Methotrexate: A Randomized Clinical Trial (TRANSIT)

Secukinumab Is Superior to Fumaric Acid Esters in Treating Subjects With Moderate to Severe Plaque Psoriasis Who Are Naïve to Systemic Treatments: Results From the Randomized Controlled PRIME Trial

Efficacy and Safety of Mirikizumab (LY3074828) in the Treatment of Moderate-To-Severe Plaque Psoriasis: Results From a Randomised Phase 2 Study

Ixekizumab Treatment for Psoriasis: Integrated Efficacy Analysis of Three Double-Blinded, Controlled Studies (UNCOVER-1, UNCOVER-2, UNCOVER-3)

060 Integrated Safety of Ixekizumab in Patients With Moderate-To-Severe Psoriasis: Results From a Pooled Analysis of 7 Clinical Trials

伊赛珠单抗对银屑病的治疗:三项双盲对照研究的综合药效分析(发现-1、发现-2、发现-3)

534 Effects on CD3, Treg and TH17 Cell Numbers in Skin Biopsies After 16-Week Mirikizumab Treatment, Evaluated by an Epigenetic Assay

A 24‐week Multicentre, Randomised, Open‐label, Parallel‐group Study Comparing the Efficacy and Safety of Ixekizumab to Fumaric Acid Esters and Methotrexate in Patients With Moderate‐to‐severe Plaque Psoriasis Naïve to Systemic Treatment

Safety of Guselkumab in Patients With Psoriasis Treated Through 100 Weeks

059 Ixekizumab Shows No Association With MACE in Patients With Moderate-To-Severe Psoriasis: An Integrated Safety Analysis of Clinical Trials